Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment

Sorafenib (SOR) is a multi-kinase inhibitor that was approved as the first-line systematic treatment agent of hepatocellular carcinoma (HCC). However, the anti-cancerous effect of SOR is dramatically impaired by the drug resistance, insufficient accumulation at tumor tissues, and limited tumor inner...

Descripción completa

Detalles Bibliográficos
Autores principales: Zan, Ying, Dai, Zhijun, Liang, Liang, Deng, Yujiao, Dong, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882497/
https://www.ncbi.nlm.nih.gov/pubmed/31735093
http://dx.doi.org/10.1080/10717544.2019.1654040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882497/
https://www.ncbi.nlm.nih.gov/pubmed/31735093
http://dx.doi.org/10.1080/10717544.2019.1654040

Ejemplares similares